Company profile for Acadia Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

ACADIA’s history is rooted in science and strong leadership in CNS research. Since the beginning, we have been dedicated to improving the lives of patients suffering from CNS disorders.At ACADIA, we are passionate about improving the lives of patients with central nervous system (CNS) disorders. We are building the foundation to become a leading biopharmaceutical company dedicated to developing and commercializing innovative...
ACADIA’s history is rooted in science and strong leadership in CNS research. Since the beginning, we have been dedicated to improving the lives of patients suffering from CNS disorders.At ACADIA, we are passionate about improving the lives of patients with central nervous system (CNS) disorders. We are building the foundation to become a leading biopharmaceutical company dedicated to developing and commercializing innovative therapies in the CNS area. ACADIA’s mission is to be the leading pharmaceutical company dedicated to the advancement of innovative medicines that improve the lives of patients with central nervous system disorders.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
3611 Valley Centre Drive, Suite 300 San Diego, CA 92130
Telephone
Telephone
+1 (858) 558-2871
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251211720018/en/Acadia-Pharmaceuticals-Announces-FDA-Approval-of-DAYBUE-STIX-trofinetide-for-Oral-Solution-a-New-Powder-Formulation-of-Trofinetide-for-the-Treatment-of-Rett-Syndrome

BUSINESSWIRE
12 Dec 2025

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219884

FDA
11 Dec 2025

https://www.businesswire.com/news/home/20251120902620/en/Acadia-Pharmaceuticals-to-Participate-in-Citis-2025-Global-Healthcare-Conference

BUSINESSWIRE
20 Nov 2025

https://www.businesswire.com/news/home/20251105491823/en/Acadia-Pharmaceuticals-Reports-Third-Quarter-2025-Financial-Results-and-Operating-Overview

BUSINESSWIRE
05 Nov 2025

https://www.businesswire.com/news/home/20251028721956/en/Acadia-Pharmaceuticals-to-Participate-at-Upcoming-Investor-Conferences

BUSINESSWIRE
28 Oct 2025

https://www.businesswire.com/news/home/20251015293381/en/Acadia-Pharmaceuticals-to-Announce-Third-Quarter-2025-Financial-Results-on-November-5-2025

BUSINESSWIRE
15 Oct 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty